Newcourt Acquisition Corp. (NCAC) Closes Psyence Deal
by Marlena Haddad on 2024-01-25 at 6:14pm

Newcourt (NASDAQ:NCAC) has closed its combination with psychedelic medicine company Psyence (CSE:PSYG) and will begin trading on The Nasdaq under the new ticker symbol ticker symbol “PBM” on January 26.

Shareholders previously approved the combination during a special meeting held on January 18.

In connection with last week’s vote, shareholders opted to redeem 929,727 shares at a redemption price of approximately $11.51 per share, removing about $10.7 million from Newcourt’s trust and leaving it with 183,294 public shares outstanding and about $2.1 million in trust.

In connection with the combination, Psyence Biomed entered into a securities purchase agreement under which it will raise up to $10 million in funding through the issuance of up to four senior secured convertible notes with a US-based investment firm. The combined company intends to use the note financing to further its clinical trials conducted in Australia.

Psyence Biomed has partnered with the Australian-based research organization iNGENu to conduct its clinical trial in palliative care. Upon successful completion of the study, the combined company plans to conduct a multinational Phase III study.

The SPAC announced its deal with Psyence in January 2023. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.

Psyence Biomedical plans to use the funds from the deal to expedite its clinical trials and expand its market presence.


ADVISORS

  • Bayline Capital Partners Inc. is acting as capital markets advisor to Psyence.
  • WeirFoulds LLP is acting as Canadian legal advisor to Psyence.
  • Morgan, Lewis & Bockius LLP is acting as U.S. legal advisor to Psyence.
  • McDermott Will & Emery LLP is acting as U.S. legal advisor to Newcourt.
Recent Posts
by Kristi Marvin on 2025-02-14 at 8:16am

At the SPAC of Dawn  Lost in the daily assault of A.I. company news are all of the “other” companies that were created in the past decade or so. The normies. These venture-backed companies that achieved unicorn status during the boom years of 2020 and 2021 have been sidelined and much has been discussed about...

by Kristi Marvin on 2025-02-14 at 6:50am

Quantum computing has been one of the hottest investment topics in the past two months and three of the leading listed companies in the space are de-SPACs. But, how close is quantum computing to generating real value and what capabilities are still years away? This week, we speak with Alan Baratz, CEO of D–Wave (NYSE:QBTS), which...

by Nicholas Alan Clayton on 2025-02-13 at 8:19am

At the SPAC of Dawn  The sudden burst of SPAC activity this week slowed down after the closing bell yesterday as the market faces a period sandwiched between CPI and PPI readouts. Yesterday’s CPI news and Fed Chair Jerome Powell’s comments before Congress did not provide an instant relief in terms of clarity on a...

by Kristi Marvin on 2025-02-12 at 5:34pm

Maywood Acquisition Corp. (NASDAQ:MAYAU) announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “MAYAU”, Thursday, February 13, 2025. Maywood will have a broad search focus and will pursue an initial business combination in any industry or geographic location. The team is led...

by Nicholas Alan Clayton on 2025-02-12 at 5:20pm

Artius II Acquisition Inc. (NASDAQ:AACBU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “AACBU”, Thursday, February 13, 2025. Artius II intends to search for a target company with a technology-enabled business with opportunities that have multiple vectors to create value post-combination....

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved